Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

New PTLD Guideline highlighted at NCCN Annual Conference

A new Guideline detailing diagnosis, workup, and treatment options for Post-Transplant Lymphoproliferative Disorder, as well as stronger recommendations for therapies in follicular lymphoma, topped the list of highlights in a presentation of the updated NCCN Guidelines for Non-Hodgkin's Lymphomas.

14 Mar 2011

Combination therapy may overcome Herceptin-resistant breast cancer

Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine.

14 Mar 2011

Number of cancer survivors rise: CDC report

Latest figures show that many Americans are surviving cancer. In fact, 40 percent of cancer survivors have outlived their diagnoses by 10 years or more.

12 Mar 2011

CytRx reports $0.4M net income for 2010 vs. $4.8M net loss for 2009

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the 12 months ended December 31, 2010, and provided a business update.

11 Mar 2011

Updated NCCN Guidelines for Breast Cancer outline expanded treatment options

Women with metastatic breast cancer have expanded treatment options for treating the disease and in the prevention of skeletal-related events as outlined in the recently updated NCCN Guidelines™ for Breast Cancer. Robert W. Carlson, MD, of Stanford Comprehensive Cancer Center and chair of the NCCN Guidelines Panel for Breast Cancer, presented these and other notable updates to the NCCN Guidelines at the NCCN 16th Annual Conference on March 10, 2011.

11 Mar 2011

Halozyme Therapeutics 2010 net loss decreases to $53.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2010.

11 Mar 2011

Groundbreaking studies presented at Prostate Cancer Research Program's IMPaCT conference

Today, the nation's most prestigious minds in prostate cancer research unveiled the findings of their groundbreaking studies at the Prostate Cancer Research Program's (PCRP's) Innovative Minds in Prostate Cancer Today (IMPaCT) conference in Orlando, Florida.

11 Mar 2011

Synta fourth-quarter total collaboration revenue decreases to $3.0 million

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today reported fourth-quarter and full-year 2010 financial results, provided an update on recent progress with its programs, and announced 2011 objectives.

11 Mar 2011

BDSI prices $15 million private placement

BioDelivery Sciences International, Inc. announces that it has received definitive commitments from institutional investors for a private placement financing yielding gross proceeds of $15 million to BDSI. The financing is expected to close today.

11 Mar 2011

DiagnoCure first quarter total revenue is $362,101 for 2011

DiagnoCure, Inc., a life sciences company commercializing high‐value cancer diagnostic tests and delivering laboratory services, today reported financial and operation results for the first quarter of fiscal 2011.

11 Mar 2011

Increase in cancer survivors underscores need for post-treatment follow-up care

The number of cancer survivors in the United States increased to 11.7 million in 2007, according to a report the Centers for Disease Control and Prevention (CDC) and the National Cancer Institute (NCI) released today. This is a nearly 20 percent increase in cancer survivors from 2001.

11 Mar 2011

CIC to host Scientific Colloquium on tumor immunotherapy in National Harbor, MD

The Cancer Immunotherapy Consortium, a program of the nonprofit Cancer Research Institute, will host its 2011 Scientific Colloquium March 17-19, 2011, at the Gaylord National Hotel and Convention Center in National Harbor, MD.

11 Mar 2011

Erlotinib, Gefitinib effective in treating certain subset of advanced NSCLC patients

LSU oncologist Vince D. Cataldo, MD, is the lead author of a review article reporting two chemotherapy drugs now indicated for second and third-line therapy in patients with advanced non-small-cell lung cancer are remarkably effective in treating a certain subset of these patients.

11 Mar 2011

Organ removal surgery through body's orifices, without any visible incisions

The Chicago Park District physical instructor needed a way to get the surgery performed without being laid up for weeks so she opted for an innovative minimally invasive procedure called Natural Orifice Translumenal Endoscopic Surgery (NOTES) that would allow surgeons to perform organ removal surgery without any visible incisions and have her back on her feet the same day.

11 Mar 2011

Layton, LHP partner to construct new Seton Medical Center in Texas

LHP Hospital Group, Inc. of Plano, Texas, has announced the selection of Layton Construction Company, Inc. of Sandy, Utah, for construction of the new Seton Medical Center Harker Heights being developed in Harker Heights, Texas, by a joint venture between LHP and the Seton Family of Hospitals.

11 Mar 2011

Sanofi-aventis, Regeneron announce results of VEGF Trap Phase III trial in second-line NSCLC

Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced results from the Phase III VITAL trial evaluating the investigational agent aflibercept (VEGF Trap) for the second-line treatment of non-small cell lung cancer (NSCLC).

11 Mar 2011

Jasco initiates pancreatic cancer research program with NCCU in Durham

Jasco Pharmaceuticals, LLC has initiated a collaborative research program with North Carolina Central University in Durham, North Carolina, focused on developing therapeutics for pancreatic cancer that function through a Pim kinase mechanism of action.

11 Mar 2011

Eisai, Epizyme partner to develop and commercialize EZH2 epigenetic enzyme

Epizyme, Inc. announced today a worldwide partnership with Eisai Co., Ltd., Tokyo, Japan to discover, develop and commercialize therapeutics targeting EZH2, an epigenetic enzyme, for the treatment of lymphoma and other cancers in genetically-defined patients.

11 Mar 2011

Idera reports $6.0 million net loss for fourth quarter 2010

Idera Pharmaceuticals, Inc. today reported financial results for the fourth quarter and year ended December 31, 2010.

10 Mar 2011

CTI announces final pixantrone clinical trial design for treatment of DLBCL

Cell Therapeutics, Inc. today announced the final clinical trial design of a randomized pivotal trial of pixantrone for the treatment of diffuse large B-cell lymphoma following discussions with the U.S. Food and Drug Administration's Division of Hematologic Products.

10 Mar 2011